Last reviewed · How we verify
EconoPred Plus
EconoPred Plus is a prednisolone formulation designed to provide cost-effective corticosteroid therapy for inflammatory and autoimmune conditions.
EconoPred Plus is a prednisolone formulation designed to provide cost-effective corticosteroid therapy for inflammatory and autoimmune conditions. Used for Inflammatory and autoimmune disorders (general indication), Rheumatoid arthritis, Systemic lupus erythematosus.
At a glance
| Generic name | EconoPred Plus |
|---|---|
| Also known as | Pred Forte |
| Sponsor | Indiana University School of Medicine |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
As a corticosteroid, prednisolone works by suppressing the immune system and reducing inflammation through glucocorticoid receptor activation. It inhibits the production of pro-inflammatory cytokines and reduces immune cell activation. The 'Plus' formulation likely refers to an optimized delivery or combination approach to enhance efficacy or tolerability while maintaining affordability.
Approved indications
- Inflammatory and autoimmune disorders (general indication)
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Other corticosteroid-responsive conditions
Common side effects
- Increased infection risk
- Hyperglycemia
- Osteoporosis
- Hypertension
- Mood changes
- Insomnia
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- OMT for Adhesive Capsulitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EconoPred Plus CI brief — competitive landscape report
- EconoPred Plus updates RSS · CI watch RSS
- Indiana University School of Medicine portfolio CI